Prognostic factors in localized extremity osteosarcoma: A systematic review

European Journal of Surgical Oncology

Volumn 35, Issue 10, 2009, Pages 1030-1036

  Bramer, J A M ^a   van Linge, J H ^b   Grimer, R J ^c   Scholten, R J P M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Bone neoplasms; Extremities; Humans; Osteosarcoma; Prognosis; Survival analysis

Indexed keywords

ALKALINE PHOSPHATASE; GLYCOPROTEIN P; LACTATE DEHYDROGENASE;

AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; DISEASE DURATION; EXTREMITY OSTEOSARCOMA; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 69949093509     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.01.011     Document Type: Review

References (57)

1. Davis A.M., Bell R.S., and Goodwin P.J. Prognostic factors in osteosarcoma: a critical review. Journal of Clinical Oncology 12 2 (1994) 423-431
2. Weeden S., Grimer R.J., Cannon S.R., Taminiau A.H., and Uscinska B.M. The effect of local recurrence on survival in resected osteosarcoma. European Journal of Cancer 37 1 (2001) 39-46
3. Wilkins R.M., Cullen J.W., Camozzi A.B., Jamroz B.A., and Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clinical Orthopaedics & Related Research 438 (2005) 128-136 Ref type: electronic citation
4. Souhami R.L., Craft A.W., Van der Eijken J.W., et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup. Lancet 350 9082 (1997) 911-917
5. Bacci G., Longhi A., Versari M., Mercuri M., Briccoli A., and Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106 5 (2006) 1154-1161
6. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology 20 3 (2002) 776-790
7. Link M.P., Goorin A.M., Horowitz M., et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi-institutional osteosarcoma study. Clinical Orthopaedics & Related Research 270 (1991) 8-14
8. Glasser D.B., Lane J.M., Huvos A.G., Marcove R.C., and Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the memorial hospital experience. Cancer 69 3 (1992) 698-708
9. Grimer R.J. Surgical options for children with osteosarcoma. Lancet Oncology 6 2 (2005) 85-92
10. Akatsuka T., Wada T., Kokai Y., et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94 5 (2002) 1397-1404
11. Baldini N., Scotlandi K., Barbanti-Brodano G., et al. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. New England Journal of Medicine 333 21 (1995) 1380-1385
12. Pakos E.E., and Ioannidis J.P. The association of p-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98 3 (2003) 581-589
13. Pakos E.E., Kyzas P.A., and Ioannidis J.P. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clinical Cancer Research 10 18 Pt 1 (2004) 6208-6214
14. Stein U., Shoemaker R.H., and Schlag P.M. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. European Journal of Cancer Part A: General Topics 32 1 (1996) 86-92
15. Trieb K., and Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. International Journal of Biochemistry & Cell Biology 33 1 (2001) 11-17
16. Saeter G., Elomaa I., Wahlqvist Y., et al. Prognostic factors in bone sarcomas. Acta Orthopaedica Scandinavica (Supplement) 68 273 (1997) 156-160
17. Hayden J.A., Cote P., and Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of Internal Medicine 144 6 (2006) 427-437
18. Harbour R., and Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 323 7308 (2001) 334-336
19. Glasser D.B., and Lane J.M. Stage IIB osteogenic sarcoma. Clinical Orthopaedics & Related Research 270 (1991) 29-39
20. Bieling P., Rehan N., Winkler P., et al. Tumor size and prognosis in aggressively treated osteosarcoma. Journal of Clinical Oncology 14 3 (1996) 848-858
21. Bacci G., Longhi A., Ferrari S., et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori 90 5 (2004) 478-484
22. Bacci G., Longhi A., Ferrari S., et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncology Reports 9 1 (2002) 171-175
23. Bacci G., Ferrari S., Mercuri M., et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthopaedica Scandinavica 69 3 (1998) 230-236
24. Ferrari S., Bertoni F., Mercuri M., et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Annals of Oncology 12 8 (2001) 1145-1150
25. Smeland S., Muller C., Alvegard T.A., et al. Scandinavian sarcoma group osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. European Journal of Cancer 39 4 (2003) 488-494
26. Enneking W.F., Spinier S.S., and Goodman M.A. Current concepts review. The surgical staging of musculoskeletal sarcoma. Journal of Bone and Joint Surgery (American) 62 6 (1980) 1027-1030
27. Rehan N., Bieling P., Winkler P., et al. Assessing the best measure of tumor size as a prognostic factor in osteosarcoma after neoadjuvant chemotherapy. Klinische Padiatrie 205 4 (1993) 200-209
28. Bauer H.C.F. DNA cytometry of osteosarcoma. Acta Orthopaedica Scandinavica (Supplement) 59 228 (1988) 5-39
29. Bentzen S.M., Poulsen H.S., Kaae S., et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer 62 1 (1988) 194-202
30. Mantadakis E., Kim G., Reisch J., et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. Journal of Pediatric Hematology Oncology 23 5 (2001) 286-289
31. Szendroi M., Papai Z., Koos R., and Illes T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. Journal of Surgical Oncology 73 2 (2000) 87-94
32. Ger L.P., Wang J.W., Lin C.C., and Wang J. Prognostic factors in 43 cases of osteosarcoma. Journal of the Formosan Medical Association 92 11 (1993) 962-968
33. Kuryu M., Ozaki T., Nishida K., Shibahara M., Kawai A., and Inoue H. Expression of CD44 variants in osteosarcoma. Journal of Cancer Research & Clinical Oncology 125 11 (1999) 646-652
34. Okada K., Hasegawa T., Yokoyama R., Beppu Y., and Itoi E. Prognostic relevance of rosette-like features in osteosarcoma. Journal of Clinical Pathology 56 11 (2003) 831-834
35. Spanier S.S., Shuster J.J., and Vander Griend R.A. The effect of local extent of the tumor on prognosis in osteosarcoma. Journal of Bone and Joint Surgery - Series A 72 5 (1990) 643-653
36. Stokkel M.P., Linthorst M.F., Borm J.J., Taminiau A.H., and Pauwels E.K. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. Journal of Cancer Research and Clinical Oncology 128 7 (2002) 393-399
37. Tomer G., Cohen I.J., Kidron D., et al. Prognostic factors in non-metastatic limb osteosarcoma: a 20-year experience of one center. International Journal of Oncology 15 1 (1999) 179-185
38. Charity R.M., Foukas A.F., Deshmukh N.S., and Grimer R.J. Vascular endothelial growth factor expression in osteosarcoma. Clinical Orthopaedics & Related Research 448 (2006) 193-198
39. Reddick W.E., Wang S., Xiong X., et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 91 12 (2001) 2230-2237
40. Uozaki H., Horiuchi H., Ishida T., Iijima T., Imamura T., and Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-s-transferase Pi, heat shock protein 27, and lung resistance- related protein) in osteosarcoma: relationship with poor prognosis. Cancer 79 12 (1997) 2336-2344
41. Wunder J.S., Bull S.B., Aneliunas V., et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. Journal of Clinical Oncology 18 14 (2000) 2685-2694
42. Baldini N., Scotlandi K., Serra M., et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. Journal of Orthopaedic Research 17 5 (1999) 629-632
43. Chan H.S., Grogan T.M., Haddad G., DeBoer G., and Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. Journal of National Cancer Institute 89 22 (1997) 1706-1715
44. Hornicek F.J., Gebhardt M.C., Wolfe M.W., et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clinical Orthopaedics & Related Research 373 (2000) 11-17
45. Serra M., Scotlandi K., Manara M.C., et al. Analysis of p-glycoprotein expression in osteosarcoma. European Journal of Cancer 31A 12 (1995) 1998-2002
46. Yamamoto O., Wada T., Takahashi M., Yamawaki S., and Ishii S. Prognostic value of p-glycoprotein expression in bone and soft-tissue sarcoma. International Journal of Clinical Oncology 5 3 (2000) 164-170
47. Park Y.B., Kim H.S., Oh J.H., and Lee S.H. The co-expression of P53 protein and p-glycoprotein is correlated to a poor prognosis in osteosarcoma. International Orthopaedics 24 6 (2001) 307-310
48. Morris C.D., Gorlick R., Huvos A.G., Heller G., Meyers P.A., and Healey J.H. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clinical Orthopaedics & Related Research 382 (2001) 59-65
49. Onda M., Matsuda S., Higaki S., et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77 1 (1996) 71-78
50. Scotlandi K., Manara M.C., Hattinger C.M., et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. European Journal of Cancer 41 9 (2005) 1349-1361
51. Gorlick R., Huvos A.G., Heller G., et al. Expression of HER2/ErbB-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology 17 9 (1999) 2781-2788
52. Kaya M., Wada T., Kawaguchi S., et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. British Journal of Cancer 86 6 (2002) 864-869
53. Kaya M., Wada T., Akatsuka T., et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research 6 2 (2000) 572-577
54. Lee Y.H., Tokunaga T., Oshika Y., et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. European Journal of Cancer 35 7 (1999) 1089-1093
55. Feugeas O., Guriec N., Babin-Boilletot A., et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. Journal of Clinical Oncology 14 2 (1996) 467-472
56. Bentzen S.M. Prognostic factor studies in oncology: osteosarcoma as a clinical example. International Journal of Radiation Oncology, Biology, Physics 49 2 (2001) 513-518
57. Dorfman H.D., and Czerniak B. Bone cancers. Cancer 75 1 Suppl. (1995) 203-210